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Copenhagen University Hospital, Department of Oncology, Rigshospitalet, Copenhagen, DenmarkIn 2013 testicular cancer (TC) represents the most curable
solid tumour. The high cure rate is associated with a signifi-
cant long-term morbidity. Long-term effects after TC treat-
ment can be divided into life-threatening (e.g. secondary
tumours and cardiovascular disease) or effects on single or-
gans (e.g. nephro-, neuro- and pulmonary toxicity, hypogo-
nadism or decreased fertility). Psychosocial effects are also a
major issue, with fatigue, influence on sexuality, work, cogni-
tive function, quality of life, lifestyle factors, etc. Some of
these side effects are discussed below, with a focus on future
studies. Testicular cancer survivors are at significantly in-
creased risk of solid tumours for at least 35 years after treat-
ment, with a higher incidence in patients who have had a
seminoma compared to non-seminoma [1,2]. However, pub-
lished studies lack detailed information concerning treat-
ment or refer to formerly used treatments.
Several studies have demonstrated increased risk of car-
diovascular disease [3–7]. A Norwegian study found a 5.7-fold
higher risk for coronary artery disease after bleomycin, etopo-
side and cisplatin (BEP) treatment, with a median observation
time of 19 years [3]. Hypogonadism, hyperlipidaemia [4] and
metabolic syndrome [4,7] have been mentioned as risk fac-
tors. Metabolic syndrome in particular could be linked to sub-
clinical testosterone deficiency.
It is necessary to increase our knowledge concerning the
impact of cisplatin-based chemotherapy, lifestyle factors
(diet, tobacco, physical activity), hypogonadism, family his-
tory concerning cardiovascular disease (CVD), alcohol, abnor-
mal blood samples and gene changes on the development of
cardiovascular disease in TC patients. Given the increased
incidence of CVD in TC patients it would be relevant to look
at genetic markers which in the general population have been
found to predispose to these diseases. To develop risk models
that include the above-mentioned factors, international coop-
eration is needed. This could make it possible to stratify TC
patients into risk groups and develop evidence-based inter-
vention according to the risk factors.
Testicular cancer patients should be tested for subclinical
hypogonadism. We know that after treatment, the serum tes-tosterone concentration is in the lower part of the normal
range [8] and that 12–16% of long-term survivors have devel-
oped hypogonadism. Most younger TC patients exhibit some
dysfunction of the Leydig cells, which is compensated by an
increase in luteinising hormone (LH) levels. Whether this
compensation is adequate in elderly TC patients is not
known. The clinical significance of low testosterone levels is
under discussion, but most people believe that a sustained
reduction in testosterone is a contributing factor in the devel-
opment of metabolic syndrome, type-2 diabetes, osteoporo-
sis, decreased quality of life and premature ageing [9].
Hypogonadism could be a significant and independent pre-
dictor for the development of CVD, and if this is the case, tes-
tosterone replacement should be examined.
All TC patients treated with cisplatin will experience a de-
cline in glomerular filtration rate (GFR). This reduction will in
some patients be reversible, whereas in others GFR shows a
permanent decrease of up to 30% or more [10,11]. There is
no long-term monitoring of renal function in TC patients
treated with cisplatin. Experimental and clinical data suggest
that hypomagnesaemia is important for the development of
nephrotoxicity [12]. There are several unanswered questions
related to nephrotoxicity in this group of patients. It is un-
known whether the natural age loss in GFR is accelerated in
TC patients treated with platinum or whether the nephrotox-
icity is exacerbated in older platinum-treated TC patients. An-
other important issue to clarify is the influence of a decline in
GFR on the development of cardiovascular disease and death
from all causes.
The high survival rate and young age of patients with TC
entails that the treatment effect on reproductive function, fer-
tility and offspring health is a very significant factor. Affected
Sertoli-cell function and impaired Leydig-cell function in a
subset of TC patients result from testicular dysgenesis syn-
drome [13] which may explain the increased incidence of oli-
go-and azospermi in TC patients both before and after
orchiectomy, but before further treatment.
Most long-term survivors after treatment for TC can be-
come biological fathers without medical assistance [14]. Yet
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the normal population. All studies concerning gonadal func-
tion in TC patients is based on data from a single department,
with a limited number of patients and few details about the
treatment.
With the development of modern assisting reproductive
techniques, even men with significant gonadal dysfunction
will be able to have children. Cryopreservation of semen, opti-
mally performed before orchiectomy, is offered in most places
in order to increase the likelihood of subsequent fatherhood.
In view of the increased opportunity and use of frozen semen
for later artificial insemination, it is important to clarify
whether pregnancies obtained with frozen semen of low
quality are subject to more abortions, stillbirths or deformed
children. These data will be essential in order to advise the
TC patients. Larger-scale data concerning fertility in patients
with TC treated with either surveillance or chemotherapy
(three or four cycles of BEP) are needed.
Data regarding the factors leading to long-term side effects
of treatment remain scarce. Molecular testing methods might
help in identifying patients at high risk for therapy-related
complications and guide risk-adapted screening and inter-
vention strategies. In recent years, screening for variations
in polymorphisms has proved to be a valuable tool to investi-
gate the genetic predisposition for late effects. There is a rel-
atively high incidence of single-nucleotide polymorphisms
(SNPs) in genes which affect the cellular response in relation
to the cytotoxic treatment for TC [15].
In order to gain further knowledge on the development of
late effects in TC patients we need to have detailed informa-
tion about treatment, to include genetic research methods,
and to study side effects over time. The hope is that increased
knowledge can lead to interventional studies with reduction
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